TrueBinding, a developer of antibody drugs, creates treatments intended for applications in immune-oncology and other disease areas. Their drugs provide novel ligands to receptors of documented checkpoint inhibitor pathways and an artificial intelligence and big data-driven platform. They offer services to their clients, including anti-cancer immunotherapy and targeted antibody drug delivery.

Investors Include:

ShangBay Capital.

Collective explained in 2 minutes

Learn how Collective's solutions enable you to manage your risk and maximize your wealth

Learn more

Our available services for this company

Lifetime IncomeCharitable Remainder Trust

Tax SavingsDonor Advised Fund